Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics

Christopher Ott's Biography



Christopher Ott, Research Fellow, Harvard School of Public Health

Dr. Christopher Ott received his PhD in molecular genetics from Northwestern University, where he studied the molecular mechanisms of transcriptional regulation of CFTR, mutations in which cause cystic fibrosis. He is currently a Leukemia & Lymphoma Society Research Fellow in the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA. His research focuses on the development of synthetic inhibitors of transcriptional regulatory proteins and their potential use as cancer therapeutics.

Christopher Ott Image

Targeting Leukemia Oncogene Expression with Bromodomain Inhibitors

Thursday, 9 May 2013 at 14:45

Add to Calendar ▼2013-05-09 14:45:002013-05-09 15:45:00Europe/LondonTargeting Leukemia Oncogene Expression with Bromodomain InhibitorsSELECTBIOenquiries@selectbiosciences.com

Bromodomain inhibitors disrupt the association of chromatin-binding proteins with transcriptionally active regions of the genome. We have developed JQ1, an inhibitor of BET bromodomains; JQ1 induces a dramatic and selective decrease in oncogene expression in leukemia cells.


Add to Calendar ▼2013-05-09 00:00:002013-05-10 00:00:00Europe/LondonEpigeneticsSELECTBIOenquiries@selectbiosciences.com